Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
Nkarta (NKTX) Stock Price & Analysis
551 Followers
NKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $16.24
Previous Close$6.64
Volume436.99K
Average Volume (3M)813.78K
Market Cap
$467.90M
Enterprise Value$308.05M
Total Cash (Recent Filing)$248.19M
Total Debt (Recent Filing)$88.34M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 08, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding70,467,620
10 Day Avg. Volume660,130
30 Day Avg. Volume813,781
Standard Deviation0.36
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$17.25Price Target Upside149.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Nkarta News
PremiumCompany Announcements
Nkarta Announces New President and Strategic Executive Shifts
PremiumCompany Announcements
Nkarta Advances Clinical Trials and Explores New Treatments
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNkarta plans to dose its first patient in the Phase I study evaluating NKX019 in r/r lupus nephritis.
Corporate StrategyThe company's strategic pivot accurately reflects increased investor enthusiasm for the potential of allogeneic cell therapies for autoimmune diseases.
Financial PerformanceThe company ended the quarter with $450M in cash/equivalents and investments, providing runway to late 2027.
Bears Say
Clinical TrialsPatient enrollment in the NKX101 AML trial was closed after preliminary data showed an aggregate CR/CRi rate of 25%, far below the 67% CR/CRi rate observed in the first 6 patients.
Product DevelopmentNkarta is halting development of NKX101 in AML after seeing suboptimal activity in a larger cohort of patients.
Research And DevelopmentClosing of the three previously announced expansion cohorts for NKX019 due to lackluster responses.
---
Ownership Overview
61.96% Insiders
10.97% Mutual Funds
7.67% Other Institutional Investors
19.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.28 and its highest was $16.24 in the past 12 months.
What is Nkarta’s market cap?
Currently, no data Available
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Aug 08, 2024 which is in 13 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on May 09, 2024. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.545 by -$0.035.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -$0.47.
How many shares outstanding does Nkarta have?
Nkarta has 70,467,620 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.545. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Nkarta?
Among the largest hedge funds holding Nkarta’s share is RA Capital Management. It holds Nkarta’s shares valued at 117M.
---
Nkarta Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (149.64% Upside)
$17.25 (149.64% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
210.28%
12-Months-Change
Fundamentals
Return on Equity
-28.33%
Trailing 12-Months
Asset Growth
25.92%
Trailing 12-Months
Company Description
Nkarta
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
---
NKTX Stock 12 Month Forecast
Average Price Target
$17.25
▲(149.64% Upside)
Technical Analysis
Adverum Biotechnologies
―
Allogene Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering NKTX
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+30.05%
reiterated a buy rating 2 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +30.05% per trade.
---